Blog

  • ‘Fairyland’ Lands October Release Date From Lionsgate and WILLA

    ‘Fairyland’ Lands October Release Date From Lionsgate and WILLA

    Lionsgate and WILLA have partnered to co-release the Sofia Coppola-produced film “Fairyland,” which will debut in theaters on Oct. 10. The film is written, produced and directed by Andrew Durham.

    Based on the acclaimed memoir of the same name by Alysia Abbott, “Fairyland” is a coming-of-age story set against the backdrop of San Francisco’s vibrant cultural scene in the 1970s and ’80s. The film chronicles a father and daughter relationship as it evolves through an era of bohemian decadence to the sober and heartbreaking era of the AIDS crisis.

    “Fairyland” stars Emilia Jones (“CODA”), Scoot McNairy (“A Complete Unknown”), Cody Fern (“American Horror Story”), Maria Bakalova (“The Apprentice”) and Bella Murphy (“Coming 2 America”), with Adam Lambert (“Glee”) and Geena Davis (“Thelma & Louise”), and introducing Nessa Dougherty.

    Amelia McPartlon Rogers, EVP of Content Strategy & Marketing Integration for the Lionsgate Motion Picture Group, said, “’Fairyland’ is a beautiful and deeply personal film that struck a real emotional chord with me. It’s an honor to continue our longstanding relationship with the American Zoetrope family and to collaborate with Sofia Coppola. This film captures a pivotal era through the lens of a father-daughter relationship that is as specific as it is universal. It’s a sharp, funny, moving portrait of identity, resilience and coming of age in a world in flux that will leave audiences spellbound.”

    The film received critical acclaim following its world premiere at the Sundance Film Festival, along with other showings at Biarritz, Palm Springs and Frameline, where it was the opening night film.

    “I was so captivated and inspired by Alysia Abbott’s memoir, not only because of the unique portrayal of this father daughter relationship, one that we hadn’t seen before, but also because of the universal themes that I think a lot of kids and parents can relate to,” said director Durham. “Films with unconventional stories are difficult to get made, but with the unwavering support from Sofia and American Zoetrope, the commitment from such a talented cast and crew, and the team at WILLA and Lionsgate, I learned if you surround yourself with people who understand and appreciate the value of the story you’re telling, then eventually everything falls into place.”

    Producer Coppola added, “I was moved by Alysia Abbott’s beautiful memoir and how Andrew interpreted it into the touching film that it is with such an important story to get out at this time. With a great cast and creative team, I’m proud to be a part of this film and put light on all kinds of families, being true to oneself, and what our generation went through.”

    For “Fairyland,” WILLA will launch an integrated impact campaign and audience engagement strategy designed to engage viewers with the timely social issues raised in the film and bolster the film’s reach.

    “With ‘Fairyland,’ Durham has crafted a deeply affecting film that brings relevant social issues to life with authenticity and heart,” said WILLA CEO and founder Elizabeth Woodward. “We are excited to be partnering with Lionsgate to distribute the film, and to create a tailored impact and audience engagement campaign around its release.”

    “Fairyland” is produced by Andrew Durham, Sofia Coppola, Megan Carlson, Laure Sudreau, Siena Oberman and Greg Lauritano. Executive producers are Roman Coppola, Michael Musante, Liz Destro, James Mockoski, Alysia Abbott, Leo Matchett, Fred Roos, Elizabeth Woodward, Jeff Sobrato, Nicole Shipley, Camille Floquet, Francesco Melzi d’Eril, Gabriele Moratti, Raffaella Viscardi, Sasha Shapiro, Rebecca Gang, Gale M. Harold III, Anton Lessine, Gary Hamilton, Ryan Hamilton, Jesse Ozeri, Susie Landau Finch, Elena Baranova, Karen Salveson, Eileen Joy Spitalny, Brooks Price and Michael Spitalny.

    “Fairyland” is an American Zoetrope production, in association with Ouroboros Entertainment LLC, Black Magic, Artemis Pictures, Walter Films, Decentralized Pictures, Safe Space Pictures, MeMo Films, 3Marys Entertainment, QED International and Lost Gang Films West.

    Continue Reading

  • “It’s an honour to wear this jersey”

    “It’s an honour to wear this jersey”

    Álvaro Carreras made his Real Madrid debut in the pre-season friendly against WSG Tirol. The defender, who was unveiled as our team’s new signing on July 15, was named in the starting XI and played 62 minutes, as Xabi Alonso’s side get in shape ahead of their LaLiga opener.
    Following the final whistle, he expressed his delight: “It’s an honour to wear this jersey. We have to continue our preparations for what’s coming up. I’ve been training with the team for a few days now, they’ve really made me feel at home. Now we have to keep working hard, because we have some fantastic challenges ahead of us.”

    Assessment of the game
    “We don’t care that it was a friendly, it was a hugely important game. It’s always important to win.”

    Mbappé
    “I’ve always said that football is easier and more beautiful with teammates like him around. I’m thrilled with all of my new teammates. With Vini Jr. on the wing, Huijsen at the back… I’m really happy.”

    A week to go until LaLiga curtain-raiser
    “I’m adapting to what the coach asks of me, what he wants his players to do. I think the team looks in great shape, we’re clear in our ideas and what we want to do, and the important thing is to win games.”

    Continue Reading

  • Elon Musk threatens Apple with lawsuit over OpenAI, sparking Sam Altman feud | Elon Musk

    Elon Musk threatens Apple with lawsuit over OpenAI, sparking Sam Altman feud | Elon Musk

    Elon Musk has threatened legal action against Apple on behalf of his artificial intelligence startup xAI, accusing the iPhone maker of favoring OpenAI and breaching antitrust regulations in managing the rankings in its App Store. The posts elicited snide responses from Sam Altman, the OpenAI CEO, and began a spat between the two former business partners on X.

    “Apple is behaving in a manner that makes it impossible for any AI company besides OpenAI to reach #1 in the App Store, which is an unequivocal antitrust violation. xAI will take immediate legal action,” Musk said in a post on X.

    In a post earlier that day, he wrote: “Hey @Apple App Store, why do you refuse to put either X or Grok in your ‘Must Have’ section when X is the #1 news app in the world and Grok is #5 among all apps? Are you playing politics?”

    OpenAI’s ChatGPT currently holds the top spot in the App Store’s “Top Free Apps” section in the US, while xAI’s Grok ranks fifth. Apple has a partnership with OpenAI that integrates ChatGPT into iPhones, iPads and Macs. Apple and xAI did not provide comment.

    Altman responded to Musk on X: “This is a remarkable claim given what I have heard alleged that Elon does to manipulate X to benefit himself and his own companies and harm his competitors and people he doesn’t like.” Musk has bent X’s algorithmic recommendations to favor his own tweets, according to multiple reports.

    Altman and Musk founded OpenAI together in 2015, but Musk left the startup and rescinded funding in 2018 after proposing to take it over, a petition other executives rebuffed. Musk has since sued the company twice over its planned transition to a for-profit enterprise, alleging “deceit of Shakespearean proportions”. Altman has cast Musk as a bitter and petty ex-partner who was jealous of the company’s success after departing.

    Musk replied to Altman’s tweet: “You got 3M views on your bullshit post, you liar, far more than I’ve received on many of mine, despite me having 50 times your follower count!”

    Altman replied to Musk multiple times, first calling his lack of views a “skill issue”, then “or bots”, and then offered a legal question of his own: “Will you sign an affidavit that you have never directed changes to the X algorithm in a way that has hurt your competitors or helped your own companies? i will apologize if so.”

    Users on X – through the community notes feature – have pointed out that a few apps besides OpenAI have taken the top spot on the App Store this year.

    Chinese AI app DeepSeek reached the No 1 spot on the platform in January, while in July, Perplexity took first place in India’s App Store – both occurring after the OpenAI and Apple partnership struck last year.

    One user asked X’s native AI, Grok, who was right in the feud. The chatbot replied: “Based on verified evidence, Sam Altman is right.”

    skip past newsletter promotion

    Musk’s comments come as regulators and rivals intensify scrutiny of Apple’s control over its App Store.

    Earlier this year, Apple was ordered to pay a fine of €500m ($581.15m) by the EU antitrust enforcer, which said the company’s restrictions prevented developers from steering users outside the App Store.

    The US Department of Justice filed an antitrust lawsuit against Apple in early 2024, accusing the iPhone maker of creating and maintaining “broad, sustained, and illegal” smartphone monopoly.

    Continue Reading

  • UN’s Haiti appeal has received lowest funding of any response plan, coordinator says

    UN’s Haiti appeal has received lowest funding of any response plan, coordinator says

    (Reuters) – The United Nations’ Haiti appeal for 2025 has received the lowest funding of any response plan worldwide, the organization’s humanitarian coordinator for the Caribbean nation said on Tuesday, as armed gangs continue to paralyze transport routes and fuel hunger.

    This year’s humanitarian response plan aims to raise over $900 million, mainly from U.N. member countries, but is just 9.2% funded, the coordinator, Ulrika Richardson, said in a briefing marked “the lowest level of funding for any response plan in the world.”

    Ukraine’s $2.63-billion appeal for this year is by comparison 38% funded, according to U.N. financial tracking data, while a $4-billion flash appeal for the Palestinian territories received $890 million, or 22% of its target.

    “We have tools, but the response from the international community is just not at par with the gravity on the ground,” Richardson said.

    More than 3,100 people have been killed this year in a conflict with heavily armed gangs that has pushed more than half the population into food insecurity and around 1.3 million from their homes. More than 8,000 people living in makeshift camps face famine-level hunger.

    A partially-deployed U.N.-backed force led by Kenya and based on voluntary contributions, deployed a year ago but has had little effect in helping a cash-strapped police force reclaim territories.

    Meanwhile, many aid organizations have had to cut back services due to the difficulty of bringing in supplies and ensuring the safety of the people they work with.

    Richardson said strangling the trafficking of arms – which the U.N. estimates are largely shipped from Florida – into Haiti was key to stopping the violence, as well as sanctions against those involved in financial support of the gangs. 


    Related Topics



    Subscribe Dunya News on YouTube

    ‘ ; r_text[1] = ” ; r_text[2] = ” ; r_text[3] = ” ; r_text[4] = ” ; r_text[5] = ” ; r_text[6] = ” ; var i = Math.floor(r_text.length * Math.random()); document.write(r_text[i]);

    Continue Reading

  • Neutrophil-targeted drug secures first FDA approval for inflammatory lung disease

    You have full access to this article via your institution.

    The FDA has approved Insmed’s brensocatib (Brinsupri)— an oral small-molecule inhibitor of dipeptidyl peptidase 1 (DPP1) — for non-cystic fibrosis bronchiectasis. It is the first drug specifically approved to treat this inflammatory lung disease, which affects an estimated 350,000–500,000 people in the USA.

    “The unmet need is massive,” says James Chalmers, a respiratory clinician scientist at the University of Dundee who led the clinical trials of brensocatib.

    Insmed’s first-in-class brensocatib could command annual sales of over US$4 billion by 2031, show consensus sales estimates on the Cortellis database. Insmed bought brensocatib from AstraZeneca in 2016 for $160 million.

    Bronchiectasis is a chronic, progressive immune-mediated disease that causes excessive mucus production, persistent cough and widening of the airways — impairing lung function. Recurrent exacerbations lead to hospitalization in many patients. Until now, treatment involved physical therapy to promote mucus clearance and antibiotics to tackle associated respiratory infection.

    Brensocatib is the first drug to target neutrophils, innate immune cells that home to sites of infection where they engulf pathogens, produce cytokines to recruit other immune cells and release antimicrobial peptides called neutrophil serine proteases (NSPs). Over-activation of neutrophils and excessive NSP production drives bronchiectasis as well as other inflammatory diseases.

    The DPP1 protease activates NSPs during neutrophil maturation in the bone marrow. By inhibiting DPP1, brensocatib disarms NSPs while sparing other effector functions of neutrophils that are needed to fight infections.

    “Brensocatib now gives you the opportunity to address the underlying disease,” says Martina Flammer, Chief Medical Officer at Insmed. “It is a game-changer.”

    In a pivotal trial in 1,721 patients who had experienced at least two exacerbations in the past year, daily brensocatib (10 mg or 25 mg) for 1 year met the primary end point, cutting the annualized rate of exacerbations by 20% versus placebo. In the high-dose group, the rate of decline in lung function was slowed to a level in line with normal ageing. Longer studies are needed to test whether the benefit to lung function persists. The drug was generally safe and well-tolerated, with no effect on the rate of infection.

    Over 20 years ago, researchers showed that DPP1-knockout mice were protected against inflammatory arthritis. But a rare genetic condition in humans who lack DPP1 dampened industry interest in the target, as these individuals have substantial abnormalities of the skin and teeth. GSK’s irreversible DPP1 inhibitor GSK2793660 also caused skin abnormalities in a phase II bronchiectasis trial and was discontinued.

    Brensocatib is a reversible covalent inhibitor that seems to have hit a sweet spot in DPP1 inhibition. Brensocatib was associated with hyperkeratosis, a thickening of the skin’s outer layer, in some patients in its phase III trial, but this was mostly mild and only led to treatment discontinuation in one patient.

    A handful of other DPP1 inhibitors are in development, including two candidates in phase III trials for bronchiectasis. Drug developers are also looking at other inflammatory indications with strong neutrophilic components for these agents (Table 1).

    “[Brensocatib is] opening up this pathway for potentially other diseases,” says Kevin Mange, Chief Development Officer at Insmed. “I think you’ll see more coming.”

    AstraZeneca retains the rights to brensocatib for asthma and chronic obstructive pulmonary disease (COPD). The company was testing brensocatib in COPD, but removed the drug from its pipeline in 2023. They declined to comment on development plans.

    Continue Reading

  • Oil Dips in Thin Summer Trading Ahead of Trump-Putin Meeting

    Oil Dips in Thin Summer Trading Ahead of Trump-Putin Meeting

    Oil inched higher as investors weighed President Donald Trump’s deferral of lofty US tariffs on China Photographer: Angel Navarrete/Bloomberg

    Oil slipped as investors weighed US President Donald Trump’s deferral of lofty tariffs on China against possible outcomes from his planned meeting with Russia’s Vladimir Putin.

    West Texas Intermediate dropped near $63 a barrel in muted summer trading, near last week’s two-month low. Trump extended for another 90 days a truce that was set to expire Tuesday. US inflation data, meanwhile, bolstered speculation the Federal Reserve will soon be able to cut interest rates.

    Most Read from Bloomberg

    Absent any major drivers, traders are looking to the summit between Trump and Putin later this week for signs sanctions on the major oil producer will be eased, although the US president on Monday downplayed expectations for a deal to end the war in Ukraine.

    The aggregate trading volume of global benchmark Brent is well below its daily average — suggesting traders are exercising caution as they seek further insight into the oil market’s outlook. Prices are down by more than 8% this month after trade and geopolitical tensions eased, while many analysts anticipate a supply glut later this year.

    Meanwhile, the US government now expects domestic oil production to fall next year, reversing years of output growth. The EIA also estimated the supply glut would increase to 1.7 million barrels a day in 2026. Looking ahead, the International Energy Agency will release its report on Wednesday.

    Most Read from Bloomberg Businessweek

    ©2025 Bloomberg L.P.

    Continue Reading

  • Yemen: ‘Regional turmoil continues to erode prospects for peace,’ Security Council hears – UN News

    1. Yemen: ‘Regional turmoil continues to erode prospects for peace,’ Security Council hears  UN News
    2. OCHA urges Security Council to “summon courage” to end inhumanity in Gaza  OCHA
    3. UN warns many Yemeni children die from hunger, calls for urgent action  Arab News
    4. UN envoy warns regional turmoil threatens fragile peace in Yemen  Anadolu Ajansı
    5. UK Urges Global Action as Yemen Faces Food Crisis  Mirage News

    Continue Reading

  • A Gigantic Jet Caught on Camera: A Spritacular Moment for NASA Astronaut Nicole Ayers!

    A Gigantic Jet Caught on Camera: A Spritacular Moment for NASA Astronaut Nicole Ayers!

    Did you see that gorgeous photo NASA astronaut Nichole Ayers took on July 3, 2025? Originally thought to be a sprite, Ayers confirmed catching an even rarer form of a Transient Luminous Events (TLEs) — a gigantic jet.   

    “Nichole Ayers caught a rare and spectacular form of a TLE from the International Space Station — a gigantic jet,” said Dr. Burcu Kosar, Principal Investigator of the Spritacular project.  

    Gigantic jets are a powerful type of electrical discharge that extends from the top of a thunderstorm into the upper atmosphere. They are typically observed by chance — often spotted by airline passengers or captured unintentionally by ground-based cameras aimed at other phenomena. Gigantic jets appear when the turbulent conditions at towering thunderstorm tops allow for lightning to escape the thunderstorm, propagating upwards toward space. They create an electrical bridge between the tops of the clouds (~20 km) and the upper atmosphere (~100 km), depositing a significant amount of electrical charge. 

    Sprites, on the other hand, are one of the most commonly observed types of TLEs — brief, colorful flashes of light that occur high above thunderstorms in the mesosphere, around 50 miles (80 kilometers) above Earth’s surface. Unlike gigantic jets, which burst upward directly from thundercloud tops, sprites form independently, much higher in the atmosphere, following powerful lightning strikes. They usually appear as a reddish glow with intricate shapes resembling jellyfish, columns, or carrots and can span tens of kilometers across. Sprites may also be accompanied or preceded by other TLEs, such as Halos and ELVEs (Emissions of Light and Very Low Frequency perturbations due to Electromagnetic Pulse Sources), making them part of a larger and visually spectacular suite of high-altitude electrical activity. The world of Transient Luminous Events is a hidden zoo of atmospheric activity playing out above the storms. Have you captured an image of a jet, sprite, or other type of TLE? Submit your photos to Spritacular.org to help scientists study these fascinating night sky phenomena! 

    Continue Reading

  • Real-World Outcomes Support Use of First-Line Palbociclib Plus ET in HR+/HER2– Advanced Breast Cancer

    Real-World Outcomes Support Use of First-Line Palbociclib Plus ET in HR+/HER2– Advanced Breast Cancer

    Image Credit: © Axel Kock – stock.adobe.com

    Findings from a real-world, retrospective study conducted in Europe showed that outcomes for patients with advanced hormone receptor (HR)–positive/HER2-negative advanced breast cancer treated with first-line palbociclib (Ibrance) plus endocrine therapy (ET) support the use of this regimen as a frontline treatment option.1

    Data published in Breast Cancer Research and Treatment demonstrated that evaluable patients treated in the United Kingdom (UK; n = 481) experienced an overall response rate (ORR) of 34.9% and a clinical benefit rate (CBR) of 80.7%. In patients from Spain (n = 251), the ORR and CBR were 43.8% and 86.1%, respectively. The respective ORR and CBR were 16.9% and 79.0% in patients from Germany (n = 124).

    In the UK cohort, the median progression-free survival (PFS) and overall survival (OS) were 33.9 months (95% CI, 28.1-41.1) and 51.3 months (95% CI, 46.6-not evaluable [NE]), respectively. The median PFS was 28.1 months (95% CI, 24.6-35.1) in patients from Spain, who also experienced a median OS that was NE (95% CI, 47.5-NE). In the German cohort, the median PFS was 48.1 months (95% CI, 34.1-NE), and the median OS was 65.2 months (95% CI, 65.2-NE).

    In the United States, palbociclib plus aromatase inhibitor is approved by the FDA as initial endocrine-based therapy for patients with HR-positive/HER2-negative advanced or metastatic breast cancer, based on data from the phase 3 PALOMA-2 trial (NCT01740427).2 Findings supporting the approval showed that patients who received palbociclib plus letrozole (n = 444) experienced an ORR of 55.3% (95% CI, 49.9%-60.7%), a median PFS of 24.8 months (95% CI, 22.1-NE), and a median OS of 53.8 months (95% CI, 49.8-59.2).

    “This [retrospective] study adds to a growing body of real-world evidence supporting the clinical effectiveness of palbociclib and other CDK4/6 inhibitor combination therapies for [patients] with HR-positive/HER2-negative advanced breast cancer,” lead study author Olga Oikonomidou, BSc, MSc, MRes, MD, PhD, FRCP, and colleagues wrote in a publication of the data.1

    Oikonomidou is a consultant medical oncologist, a senior clinical lecturer in Breast Cancer Medicine, and leader of the Breast Cancer Translational Research Group at the University of Edinburgh in Scotland.

    “It is important to supplement findings from randomized clinical trials with real-world evidence from heterogeneous populations of patients in routine clinical practice who may be ineligible or underrepresented in clinical trials,” Oikonomidou and colleagues added.

    How Real-World Palbociclib Data Were Gathered

    To conduct the retrospective study, investigators identified patients from 52 treatment centers across the UK, Spain, and Germany. The study included patients at least 18 years of age with histologically or cytologically confirmed HR-positive/HER2-negative unresectable, advanced, or metastatic breast cancer who started first-line treatment with palbociclib plus an AI during the study index period from September 1, 2016, to July 31, 2020.

    Investigators excluded patients who participated in a clinical trial evaluating a treatment for advanced, irrespective if participation occurred before or after first-line palbociclib. Patients were also excluded if they received prior treatment with any CDK4/6 inhibitor in the early-stage setting or received any CDK4/6 inhibitor–based regimen after first-line palbociclib.

    The median age at diagnosis was 63.4 years (standard deviation [SD], 12.2) in the UK cohort, 61.9 years (SD, 12.8) in the Spain cohort, and 66.6 years (SD, 12.8) in the Germany cohort. Most patients were female (UK, 100%; Spain, 98.8%; Germany, 99.2%) and White (75.9%; 92.8%; 87.1%). The median duration of follow-up was 33.7 months in the UK group, 32.7 months in the Spain group, and 32.6 months in the Germany group.

    The majority of patients in the UK cohort (62.0%) and Spain cohort (55.0%) were initially diagnosed with early-stage breast cancer, whereas most patients in the Germany cohort had de novo advanced disease (49.2%). Most patients in all 3 groups had a disease-free interval of more than 12 months (UK, 59.1%; Spain, 68.8%; Germany, 52.5%) and had 1 distant metastatic site (43.2%; 52.5%; 52.5%).

    Across the 3 cohorts, patients had approximately 2 comorbidities at baseline, with the most common comprising hypertension (22.9%-45.2%), diabetes without end-organ damage (5.6%-12.1%), and depression (8.1%-11.6%).

    Study Limitations

    Oikonomidou and colleagues explained that data provided for this study were from centers willing to participate, meaning they may not be generalizable to other sites in different countries. They also noted that the study lacked a comparator arm, and sample sizes were limited for all 3 countries.

    Additionally, since the study did not include patients who received subsequent CDK4/6 inhibitor–based regimens in the second or third line of therapy, study authors explained that these results may not be representative of this full patient population.

    References

    1. Oikonomidou O, Beresford MJ, Galve-Calvo E, et al. Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe. Breast Cancer Res Treat. Published online August 6, 2025. doi:10.1007/s10549-025-07707-5
    2. Ibrance. Prescribing information. Updated April 2025. Accessed August 12, 2025. https://labeling.pfizer.com/ShowLabeling.aspx?id=2191#section-12

    Continue Reading

  • Trading platform eToro's CEO highlights retail investor surge as profit beats estimates – Reuters

    1. Trading platform eToro’s CEO highlights retail investor surge as profit beats estimates  Reuters
    2. EToro Posts 26% Jump In Q2 Revenue As Assets Climbs Past $17 Billion  FinanceFeeds
    3. eToro’s Resilient ECC Performance and Growth Prospects Amid Crypto Challenges: A Buy Recommendation by James Yaro  TipRanks
    4. EToro Posts Strong Results Thanks to Retail Trading Surge for Stocks and Crypto  Barron’s
    5. eToro Q3 Net Income Hits $30.2 Million Amid Market Volatility  AInvest

    Continue Reading